Table 2.
Patient clinicopathological characteristics of positive and negative group in C1TC and SAHH.
| C1TC | SAHH | ||||||
|---|---|---|---|---|---|---|---|
| Positive n = 31 |
Negative n = 18 |
P value | Positive n = 31 |
Negative n = 18 |
P value | ||
| Age (years) | Median (range) | 65 (47–81) | 68 (44–77) | 0.424 | 66 (44–79) | 65 (48–81) | 0.618 |
| Sex | Male:female | 18:13 | 10: 8 | 0.864 | 19:12 | 9:9 | 0.442 |
| CA19-9 (U/mL) | Median (range) | 40.5 (0.6–1018) | 62.6 (1.5–890.3) | 0.494 | 48.5 (0.6–649.4) | 29.5 (1.6–1018) | 0.604 |
| Resectability classification | R:BR | 22:9 | 16:2 | 0.131 | 25:6 | 13:5 | 0.500 |
| Location of the tumor | Head:body-tail | 18:13 | 9:9 | 0.585 | 18:13 | 9:9 | 0.585 |
| Tumor size (mm) | Median (range) | 25 (0–42) | 25 (4–35) | 0.853 | 25 (0–42) | 25 (4–40) | 0.526 |
| Anterior serosal invasion | Positive:negative | 22:9 | 15:3 | 0.322 | 23:8 | 14:4 | 0.778 |
| Retroperitoneal invasion | Positive:negative | 24:7 | 14:4 | 0.977 | 24:7 | 14:4 | 0.977 |
| Portal vein invasion | Positive:negative | 6:25 | 4:14 | 0.811 | 5:26 | 5:13 | 0.336 |
| Lymph node metastasis | Positive:negative | 15:16 | 13:5 | 0.100 | 19:12 | 9:9 | 0.442 |
| Residual cancer (R1) | R0:R1 | 28:3 | 16:2 | 0.874 | 28:3 | 16:2 | 0.874 |